The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
Open accessAbstract
Chronic hepatitis B virus (HBV) infection is prevalent, deadly and seldom cured due to the persistence of viral episomal DNA (cccDNA) in infected cells. Newly developed genome engineering tools may offer the ability to directly cleave viral DNA, thereby promoting viral clearance. Here, we show that the CRISPR/Cas9 system can specifically target and cleave conserved regions in the HBV genome, resulting in robust suppression of viral gene expression and replication. Upon sustained expression of Cas9 and appropriately chosen guide RNAs, we demonstrate cleavage of cccDNA by Cas9 and a dramatic reduction in both cccDNA and other parameters of viral gene expression and replication. Thus, we show that directly targeting viral episomal DNA is a novel therapeutic approach to control the virus and possibly cure patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationRepurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 1×
“While nuclease-deficient Cas9 also reduced viral 3.5kb RNA abundance in this system, this finding fits with other reports that dCas9 binding can inhibit transcription in mammalian cells 15 .”
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationIn vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Self-citationYan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, B., Wang, H., et al. (2012) · eLife · doi:10.7554/elife.00049 · Cited by 2,115
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Self-citationSells, M. A., Chen, M. L., & Acs, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.4.1005 · Cited by 1,117
THE MOLECULAR BIOLOGY OF THE HEPATITIS B VIRUSES
Ganem, D., & Varmus, H. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003251 · Cited by 1,084
Dienstag, J. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801644 · Cited by 961
CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea
Marraffini, L. A., & Sontheimer, E. J. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2749 · Cited by 919
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., et al. (2014) · Science · doi:10.1126/science.1243462 · Cited by 893
The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli
Sapranauskas, R., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., & Siksnys, V. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr606 · Cited by 834
Lin, Y., Cradick, T. J., Brown, M. T., Deshmukh, H., Ranjan, P., Sarode, N., Wile, B. M., Vertino, P. M., Stewart, F. J., & Bao, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku402 · Cited by 634
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405186111 · Cited by 527
The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo
Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386
Targeting Hepatitis B Virus With CRISPR/Cas9
Seeger, C., & Sohn, J. A. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.68 · Cited by 294
Bloom, K., Ely, A., Mussolino, C., Cathomen, T., & Arbuthnot, P. (2013) · Molecular Therapy · doi:10.1038/mt.2013.170 · Cited by 217
Zhen, S., Hua, L., Liu, Y.-H., Gao, L.-C., Fu, J., Wan, D.-Y., Dong, L.-H., Song, H.-F., & Gao, X. (2015) · Gene Therapy · doi:10.1038/gt.2015.2 · Cited by 215
Kennedy, E. M., Bassit, L. C., Mueller, H., Kornepati, A. V. R., Bogerd, H. P., Nie, T., Chatterjee, P., Javanbakht, H., Schinazi, R. F., & Cullen, B. R. (2015) · Virology · doi:10.1016/j.virol.2014.12.001 · Cited by 209
Pre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B Virus
Glebe, D., Aliakbari, M., Krass, P., Knoop, E. V., Valerius, K. P., & Gerlich, W. H. (2003) · Journal of Virology · doi:10.1128/jvi.77.17.9511-9521.2003 · Cited by 175
Chen, J., Zhang, W., Lin, J., Wang, F., Wu, M., Chen, C., Zheng, Y., Peng, X., Li, J., & Yuan, Z. (2014) · Molecular Therapy · doi:10.1038/mt.2013.212 · Cited by 159
Weber, N. D., Stone, D., Sedlak, R. H., Feelixge, H. S. D. S., Roychoudhury, P., Schiffer, J. T., Aubert, M., & Jerome, K. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097579 · Cited by 122
Enhancer I Predominance in Hepatitis B Virus Gene Expression
Doitsh, G., & Shaul, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.4.1799-1808.2004 · Cited by 90
Glenn, J. F. (1967) · The Journal of Urology · doi:10.1016/s0022-5347(17)62816-7 · Cited by 75
Lewis, D. L., & Wolff, J. A. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)92020-4 · Cited by 56
Getting Rid of a Persistent Troublemaker to Cure Hepatitis
Shlomai, A., & Rice, C. M. (2014) · Science · doi:10.1126/science.1252186 · Cited by 13
Self-citation
Cited by
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Applications of CRISPR technologies in research and beyond
Barrangou, R., & Doudna, J. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3659 · Cited by 1,005
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Metadata
- Authors
- Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N.
- Venue
- Scientific Reports
- Published
- 2015-06-02
- Volume
- 5
- Issue
- 1
- Pages
- 10833-10833
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2286872394
- Cited by
- 304
- References
- 28
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.